| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 397 | 2017 |
| Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations B Will, L Zhou, TO Vogler, S Ben-Neriah, C Schinke, R Tamari, Y Yu, ... Blood, The Journal of the American Society of Hematology 120 (10), 2076-2086, 2012 | 274 | 2012 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 246 | 2016 |
| Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 237 | 2017 |
| IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreyro, T Bhagat, ... Blood, The Journal of the American Society of Hematology 125 (20), 3144-3152, 2015 | 196 | 2015 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 153 | 2019 |
| Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma JE McDonald, MM Kessler, MW Gardner, AF Buros, JA Ntambi, S Waheed, ... Clinical Cancer Research 23 (8), 1981-1987, 2017 | 133 | 2017 |
| Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis CJ Heuck, J Mehta, T Bhagat, K Gundabolu, Y Yu, S Khan, G Chrysofakis, ... The Journal of Immunology 190 (6), 2966-2975, 2013 | 132 | 2013 |
| Aberrant DNA methylation in malignant melanoma C Schinke, Y Mo, Y Yu, K Amiri, J Sosman, J Greally, A Verma Melanoma research 20 (4), 253-265, 2010 | 122 | 2010 |
| Long-term outcomes after autologous stem cell transplantation for multiple myeloma KK Nishimura, B Barlogie, F van Rhee, M Zangari, BA Walker, ... Blood advances 4 (2), 422-431, 2020 | 110 | 2020 |
| The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma L Rasche, EJ Angtuaco, TL Alpe, GH Gershner, JE McDonald, RS Samant, ... Blood, The Journal of the American Society of Hematology 132 (1), 59-66, 2018 | 104 | 2018 |
| The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma EM Boyle, S Deshpande, R Tytarenko, C Ashby, Y Wang, MA Bauer, ... Nature communications 12 (1), 293, 2021 | 98 | 2021 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 85 | 2017 |
| Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis F Mazahreh, L Mazahreh, C Schinke, S Thanendrarajan, M Zangari, ... Blood advances 7 (13), 3069-3074, 2023 | 84 | 2023 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 77 | 2017 |
| Signal transduction inhibitors in treatment of myelodysplastic syndromes L Bachegowda, O Gligich, I Mantzaris, C Schinke, D Wyville, T Carrillo, ... Journal of hematology & oncology 6, 1-11, 2013 | 65 | 2013 |
| Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). CD Schinke, C Touzeau, MC Minnema, NWCJ van de Donk, ... Journal of Clinical Oncology 41 (16_suppl), 8036-8036, 2023 | 63 | 2023 |
| Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma FE Davies, A Rosenthal, L Rasche, NM Petty, JE McDonald, JA Ntambi, ... Haematologica 103 (6), 1047, 2018 | 62 | 2018 |
| Stem cell origin of myelodysplastic syndromes HK Elias, C Schinke, S Bhattacharyya, B Will, A Verma, U Steidl Oncogene 33 (44), 5139-5150, 2014 | 58 | 2014 |
| Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease M Mohan, A Buros, P Mathur, N Gokden, M Singh, S Susanibar, ... American Journal of Hematology 92 (8), 739-745, 2017 | 56 | 2017 |
